[{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Isoamyl Nitrite","moa":"ANP receptor 1","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ BARDA"}]

Find Clinical Drug Pipeline Developments & Deals for Isoamyl Nitrite

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Study evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SIAN (stabilized isoamyl nitrite), a treatment being developed for known or suspected acute cyanide poisoning.

                          Brand Name : SIAN

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 11, 2022

                          Lead Product(s) : Isoamyl Nitrite

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase I

                          Sponsor : BARDA

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank